Since the clinical cohort examining the relationship between plasma S100A1 expression and immunotherapy outcome was comprised of samples mainly from patients with lung cancer and LLC is characterized by an immunosuppressive TME and resistance to immunotherapy,20 we selected the LLC lung cancer model to further investigate the phenotypic effect of S100a1 loss. This evidence concerns the gene S100A1 and lung carcinoma.